Press Releases

Date Title
February 11, 2021
Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Topline results from open-label safety study (NORSE THREE) on target for Q2 2021 MONMOUTH JUNCTION, N.J. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of
February 4, 2021
Outlook Therapeutics’ Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Through Planned BLA Submission
Overallotment option on recent public offering partially exercised by underwriter Closed concurrent private placement for $3.0 million gross proceeds Aggregate gross proceeds of $41.6 million strengthens financial position and provides strategic optionality to maximize stockholder value MONMOUTH
February 2, 2021
Outlook Therapeutics Announces Closing of $35.0 Million Bought Deal
MONMOUTH JUNCTION, N.J. , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today
January 28, 2021
Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million
MONMOUTH JUNCTION, N.J. , Jan. 28, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications,
January 28, 2021
Outlook Therapeutics Announces $10.0 Million Bought Deal Offering of Common Stock
MONMOUTH JUNCTION, N.J. , Jan. 28, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today
January 12, 2021
Leading Ophthalmology Organization Launches Podcast Video with Firas Rahhal, MD, to Explore the Genesis and Promise of Outlook Therapeutics’ ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Leading retina clinician Dr. Rahhal discusses the market need for an FDA-approved ophthalmic bevacizumab for treating wet AMD and other retinal diseases Terry Dagnon , COO, and Jeff Evanson , CCO, of Outlook Therapeutics share the clinical rationale and regulatory framework for developing ONS-5010
January 5, 2021
Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
MONMOUTH JUNCTION, N.J. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence
December 23, 2020
Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update
All planned clinical trials for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) wet AMD BLA now fully enrolled or completed Pivotal data expected in mid-2021 from ongoing, fully enrolled Phase 3 registration trial for ONS-5010 (NORSE TWO) with new BLA filing expected in second half of 2021 MONMOUTH
December 1, 2020
Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
MONMOUTH JUNCTION, N.J. , Dec. 01, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced today that it has received
November 19, 2020
Outlook Therapeutics Announces Creation of Global Retina Advisory Council
Advisory Co uncil to collaborate on ou t reach to retinal clinicians to support development and commercialization of ONS-5010, an investigational ophthalmic formulation of bevac i zumab MONMOUTH JUNCTION, N.J. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.
Displaying 21 - 30 of 129